Papers

Home
Papers

Export citation

Format

Download

@article{Aslan2016,
  abstract = {Spliceosome mutations are frequently observed in patients with myelodysplastic syndromes (MDS). However, it is largely unknown how these mutations contribute to the disease. MicroRNAs (miRNAs) are small noncoding RNAs, which have been implicated in most human cancers due to their role in post transcriptional gene regulation. The aim of this study was to analyze the impact of spliceosome mutations on the expression of miRNAs in a cohort of 34 MDS patients. In total, the expression of 76 miRNAs, including mirtrons and splice site overlapping miRNAs, was accurately quantified using reverse transcriptase quantitative PCR. The majority of the studied miRNAs have previously been implicated in MDS. Stably expressed miRNA genes for normalization of the data were identified using GeNorm and NormFinder algorithms. High-resolution melting assays covering all mutational hotspots within SF3B1, SRSF2, and U2AF1 (U2AF35) were developed, and all detected mutations were confirmed by Sanger sequencing. Overall, canonical miRNAs were downregulated in spliceosome mutated samples compared to wild-type (P = 0.002), and samples from spliceosome mutated patients clustered together in hierarchical cluster analyses. Among the most downregulated miRNAs were several tumor-suppressor miRNAs, including several let-7 family members, miR-423, and miR-103a. Finally, we observed that the predicted targets of the most downregulated miRNAs were involved in apoptosis, hematopoiesis, and acute myeloid leukemia among other cancer- and metabolic pathways. Our data indicate that spliceosome mutations may play an important role in MDS pathophysiology by affecting the expression of tumor suppressor miRNA genes involved in the development and progression of MDS.},
  author = {Aslan, Derya and Garde, Christian and Nygaard, Mette Katrine and Helbo, Alexandra Søgaard and Dimopoulos, Konstantinos and Hansen, Jakob Werner and Severinsen, Marianne Tang and Treppendahl, Marianne Bach and Sjø, Lene Dissing and Grønbæk, Kirsten and Kristensen, Lasse Sommer},
  doi = {10.18632/oncotarget.7127},
  month = {feb},
  title = {Tumor suppressor microRNAs are downregulated in myelodysplastic syndrome with spliceosome mutations},
  url = {http://www.impactjournals.com/oncotarget/index.php?journal=oncotarget&page=article&op=download&path%5B%5D=7127&path%5B%5D=20296},
  year = {2016}
}

@article{Ballegaard2017,
  author = {Ballegaard, Vibe and Ralfkiaer, Ulrik and Pedersen, Karin K. and Hove, Malene and Koplev, Simon and Brændstrup, Peter and Ryder, Lars P. and Madsen, Hans O. and Gerstoft, Jan and Grønbæk, Kirsten and Nielsen, Susanne D.},
  doi = {10.1097/qai.0000000000001191},
  journal = {Journal of Acquired Immune Deficiency Syndromes},
  month = {apr},
  pages = {e104-e113},
  title = {MicroRNA-210, MicroRNA-331, and MicroRNA-7 Are Differentially Regulated in Treated HIV-1–Infected Individuals and Are Associated With Markers of Systemic Inflammation: },
  url = {https://oadoi.org/10.1097/qai.0000000000001191},
  volume = {74},
  year = {2017}
}

@misc{da Cunha-Bang2016,
  author = {da Cunha-Bang, Caspar and Rostgaard, Klaus and Simonsen, Jacob and Geisler, Christian H. and Frederiksen, Henrik and Hjalgrim, Henrik and Grønbæk, Kirsten and Niemann, Carsten Utoft},
  month = {jan},
  title = {Increased Risk of Second Hematological and Non-Hematological Malignancies in CLL Patients Treated with Chemotherapy As Compared to Untreated Patients and Matched Controls},
  year = {2016}
}

@article{Eskelund2016,
  abstract = {In recent decades, the prognosis of Mantle Cell Lymphoma (MCL) has been significantly improved by intensified first-line regimens containing cytarabine, rituximab and consolidation with high-dose-therapy and autologous stem cell transplantation. One such strategy is the Nordic MCL2 regimen, developed by the Nordic Lymphoma Group. We here present the 15-year updated results of the Nordic MCL2 study after a median follow-up of 114years: For all patients on an intent-to-treat basis, the median overall and progression-free survival was 127 and 85years, respectively. The MCL International Prognostic Index (MIPI), biological MIPI, including Ki67 expression (MIPI-B) and the MIPI-B including mIR-18b expression (MIPI-B-miR), in particular, significantly divided patients into distinct risk groups. Despite very long response durations of the low and intermediate risk groups, we observed a continuous pattern of relapse and the survival curves never reached a plateau. In conclusion, despite half of the patients being still alive and 40% in first remission after more than 12years, we still see an excess disease-related mortality, even among patients experiencing long remissions. Even though we consider the Nordic regimen as a very good choice of regimen, we recommend inclusion in prospective studies to explore the benefit of novel agents in the frontline treatment of MCL.},
  author = {Eskelund, Christian W. and Kolstad, Arne and Jerkeman, Mats and Räty, Riikka and Laurell, Anna and Eloranta, Sandra and Smedby, Karin E. and Husby, Simon and Pedersen, Lone B. and Andersen, Niels S. and Eriksson, Mikael and Kimby, Eva and Bentzen, Hans and Kuittinen, Outi and Lauritzsen, Grete F. and Nilsson-Ehle, Herman and Ralfkiaer, Elisabeth and Ehinger, Mats and Sundstrom, Christer and Delabie, Jan and Karjalainen-Lindsberg, Marja-Liisa and Workman, Christopher T. and Garde, Christian and Elonen, Erkki and Brown, Peter and Gronbaek, Kirsten and Geisler, Christian H.},
  doi = {10.1111/bjh.14241},
  journal = {British Journal of Haematology},
  month = {nov},
  pages = {410-418},
  title = {15-year follow-up of the Second Nordic Mantle Cell Lymphoma trial (MCL2) ; prolonged remissions without survival plateau},
  url = {http://orbit.dtu.dk/ws/files/125132306/15_year_follow_up_of_the_Second_Nordic_Mantle_Cell_Lymphoma_trial_MCL2_.pdf},
  volume = {175},
  year = {2016}
}

@article{Glenthøj2016,
  author = {Glenthøj, Andreas and Ørskov, Andreas and Hansen, Jakob and Hadrup, Sine and O’Connell, Casey and Grønbæk, Kirsten},
  doi = {10.3390/ijms17060944},
  journal = {International Journal of Molecular Sciences},
  month = {jun},
  pages = {944},
  title = {Immune Mechanisms in Myelodysplastic Syndrome},
  url = {https://doi.org/10.3390/ijms17060944},
  volume = {17},
  year = {2016}
}

@article{Hansen2016,
  author = {Hansen, Jakob Werner and Westman, Maj Karoline and Sjö, Lene Dissing and Saft, Leonie and Kristensen, Lasse Sommer and Ørskov, Andreas Due and Treppendahl, Marianne and Andersen, Mette Klarskov and Grønbaek, Kirsten},
  doi = {10.1002/ajh.24554},
  journal = {American Journal of Hematology},
  month = {nov},
  pages = {1234-1238},
  title = {Mutations in idiopathic cytopenia of undetermined significance assist diagnostics and correlate to dysplastic changes: Mutations in Idiopathic Cytopenia of Undetermined Significance},
  url = {https://oadoi.org/10.1002/ajh.24554},
  volume = {91},
  year = {2016}
}

@article{Helbo2017,
  abstract = {Chromatin is structurally involved in the transcriptional regulation of all genes. While the nucleosome positioning at RNA polymerase II (pol II) promoters has been extensively studied, less is known about the chromatin structure at pol III promoters in human cells. We use a high-resolution analysis to show substantial differences in chromatin structure of pol II and pol III promoters, and between subtypes of pol III genes. Notably, the nucleosome depleted region at the transcription start site of pol III genes extends past the termination sequences, resulting in nucleosome free gene bodies. The +1 nucleosome is located further downstream than at pol II genes and furthermore displays weak positioning. The variable position of the +1 location is seen not only within individual cell populations and between cell types, but also between different pol III promoter subtypes, suggesting that the +1 nucleosome may be involved in the transcriptional regulation of pol III genes. We find that expression and DNA methylation patterns correlate with distinct accessibility patterns, where DNA methylation associates with the silencing and inaccessibility at promoters. Taken together, this study provides the first high-resolution map of nucleosome positioning and occupancy at human pol III promoters at specific loci and genome wide.},
  author = {Helbo, Alexandra Søgaard and Lay, Fides D. and Jones, Peter A. and Liang, Gangning and Grønbæk, Kirsten},
  doi = {10.1038/srep41947},
  month = {feb},
  title = {Nucleosome Positioning and NDR Structure at RNA Polymerase III Promoters},
  url = {http://doi.org/10.1038/srep41947},
  year = {2017}
}

@article{Kolstad2017,
  author = {Kolstad, Arne and Pedersen, Lone Bredo and Eskelund, Christian W. and Husby, Simon and Grønbæk, Kirsten and Jerkeman, Mats and Laurell, Anna and Räty, Riikka and Elonen, Erkki and Andersen, Niels Smedegaard and Brown, Peter deNully and Kimby, Eva and Bentzen, Hans and Sundström, Christer and Ehinger, Mats and Karjalainen-Lindsberg, Marja-Liisa and Delabie, Jan and Ralfkiær, Elisabeth and Fagerli, Unn-Merete and Nilsson-Ehle, Herman and Lauritzsen, Grete Fossum and Kuittinen, Outi and Niemann, Carsten and Geisler, Christian Hartman},
  doi = {10.1016/j.bbmt.2016.12.634},
  journal = {Biology of Blood and Marrow Transplantation},
  month = {mar},
  pages = {428-435},
  title = {Molecular Monitoring after Autologous Stem Cell Transplantation and Preemptive Rituximab Treatment of Molecular Relapse; Results from the Nordic Mantle Cell Lymphoma Studies (MCL2 and MCL3) with Median Follow-Up of 8.5 Years},
  url = {https://doi.org/10.1016/j.bbmt.2016.12.634},
  volume = {23},
  year = {2017}
}

@article{Kristensen2016,
  abstract = {Abstract Background The prognostic value of aberrant DNA methylation of cell-free circulating DNA in plasma has not previously been evaluated in diffuse large B cell lymphoma (DLBCL). The aim of this study was to investigate if aberrant promoter DNA methylation can be detected in plasma from DLBCL patients and to evaluate this as a prognostic marker. Furthermore, we wanted to follow possible changes in methylation levels during treatment. Seventy-four patients were enrolled in the study, of which 59 received rituximab and CHOP-like chemotherapy. Plasma samples were collected from all patients at the time of diagnosis and from 14 healthy individuals used as controls. In addition, plasma samples were collected during and after treatment for surviving patients. In total, 158 plasma samples were analyzed for DNA methylation in the promoter regions of DAPK (DAPK1), DBC1, MIR34A, and MIR34B/C using pyrosequencing. Results Aberrant methylation levels at the time of diagnosis were detected in 19, 16, 8, and 10 % of the DLBCL plasma samples for DAPK1, DBC1, MIR34A, and MIR34B/C, respectively. DAPK1 methylation levels were significantly correlated with DBC1 and MIR34B/C methylation levels (P },
  author = {Kristensen, Lasse Sommer and Hansen, Jakob Werner and Kristensen, Søren Sommer and Tholstrup, Dorte and Harsløf, Laurine Bente Schram and Pedersen, Ole Birger and De Nully Brown, Peter and Grønbæk, Kirsten},
  doi = {10.6084/m9.figshare.c.3634751},
  journal = {Clinical Epigenetics},
  month = {jan},
  title = {Aberrant methylation of cell-free circulating DNA in plasma predicts poor outcome in diffuse large B cell lymphoma},
  url = {https://doi.org/10.1186/s13148-016-0261-y},
  volume = {8},
  year = {2016}
}

@misc{Kristensen2016_2,
  abstract = {Details of the pyrosequencing assays. (TIF 14 kb)},
  author = {Kristensen, Lasse and Hansen, Jakob and Kristensen, Søren and Tholstrup, Dorte and Harsløf, Laurine and Pedersen, Ole and De Nully Brown, Peter and Grønbæk, Kirsten},
  doi = {10.6084/m9.figshare.c.3634751_d3},
  month = {jan},
  title = {Additional file 1: Table S1. of Aberrant methylation of cell-free circulating DNA in plasma predicts poor outcome in diffuse large B cell lymphoma},
  url = {http://dx.doi.org/10.6084/m9.figshare.c.3634751_D3},
  year = {2016}
}

@misc{Kristensen2016_3,
  abstract = {DAPKI methylation levels according to methylation levels of the other markers. (a) DBCI. (b) MIR34A. (c) MIR34B/C. (TIF 990 kb)},
  author = {Kristensen, Lasse and Hansen, Jakob and Kristensen, Søren and Tholstrup, Dorte and Harsløf, Laurine and Pedersen, Ole and De Nully Brown, Peter and Grønbæk, Kirsten},
  doi = {10.6084/m9.figshare.c.3634751_d4},
  month = {jan},
  title = {Additional file 2: Figure S1. of Aberrant methylation of cell-free circulating DNA in plasma predicts poor outcome in diffuse large B cell lymphoma},
  url = {http://dx.doi.org/10.6084/m9.figshare.c.3634751_D4},
  year = {2016}
}

@misc{Kristensen2016_4,
  abstract = {Methylation levels according to DNA concentrations. (a) DAPKI. (b) DBCI (c) MIR34A. (d) MIR34B/C. (TIF 1 mb)},
  author = {Kristensen, Lasse and Hansen, Jakob and Kristensen, Søren and Tholstrup, Dorte and Harsløf, Laurine and Pedersen, Ole and De Nully Brown, Peter and Grønbæk, Kirsten},
  doi = {10.6084/m9.figshare.c.3634751_d1},
  month = {jan},
  title = {Additional file 3: Figure S2. of Aberrant methylation of cell-free circulating DNA in plasma predicts poor outcome in diffuse large B cell lymphoma},
  url = {http://dx.doi.org/10.6084/m9.figshare.c.3634751_D1},
  year = {2016}
}

@misc{Kristensen2016_5,
  abstract = {Overall survival according to DNA concentrations. (TIF 593 kb)},
  author = {Kristensen, Lasse and Hansen, Jakob and Kristensen, Søren and Tholstrup, Dorte and Harsløf, Laurine and Pedersen, Ole and De Nully Brown, Peter and Grønbæk, Kirsten},
  doi = {10.6084/m9.figshare.c.3634751_d2},
  month = {jan},
  title = {Additional file 4: Figure S3. of Aberrant methylation of cell-free circulating DNA in plasma predicts poor outcome in diffuse large B cell lymphoma},
  url = {http://dx.doi.org/10.6084/m9.figshare.c.3634751_D2},
  year = {2016}
}

@article{Kristensen2016_6,
  author = {Kristensen, Lasse S. and Michaelsen, Signe R. and Dyrbye, Henrik and Aslan, Derya and Grunnet, Kirsten and Christensen, Ib J. and Poulsen, Hans S. and Grønbæk, Kirsten and Broholm, Helle},
  doi = {10.1093/jnen/nlv024},
  journal = {Journal of Neuropathology and Experimental Neurology},
  month = {mar},
  pages = {246-255},
  title = {Assessment of Quantitative and Allelic MGMT Methylation Patterns as a Prognostic Marker in Glioblastoma.},
  url = {https://academic.oup.com/jnen/article-pdf/75/3/246/17420329/nlv024.pdf},
  volume = {75},
  year = {2016}
}

@article{Liu2016,
  author = {Liu, Minmin and Ohtani, Hitoshi and Zhou, Wanding and Ørskov, Andreas Due and Charlet, Jessica and Zhang, Yang W. and Shen, Hui and Baylin, Stephen B. and Liang, Gangning and Grønbæk, Kirsten and Jones, Peter A.},
  doi = {10.1073/pnas.1612262113},
  journal = {Proceedings of the National Academy of Sciences},
  month = {aug},
  pages = {10238-10244},
  title = {Vitamin C increases viral mimicry induced by 5-aza-2′-deoxycytidine},
  url = {http://www.pnas.org/content/113/37/10238.full.pdf},
  volume = {113},
  year = {2016}
}

@misc{Munch-Petersen2016,
  abstract = {Clinical data in 107 PCNSL patients and TP53, MIR34A, and DAPK subgroups. Tables S2a-b. Disease status (a), and treatment at relapse/progression (b). Tables S3a-d. Immunohistochemical marker expression in 107 PCNSL patients and TP53, MIR34A, and DAPK subgroups. (PDF 534 kb)},
  author = {Munch-Petersen, Helga and Asmar, Fazila and Dimopoulos, Konstantinos and Areškevičiūtė, Aušrinė and Brown, Peter and Girkov, Mia and Pedersen, Anja and Sjö, Lene and Heegaard, Steffen and Broholm, Helle and Kristensen, Lasse and Ralfkiaer, Elisabeth and Grønbæk, Kirsten},
  doi = {10.6084/m9.figshare.c.3595559_d1},
  month = {jan},
  title = {Additional file 2: Tables S1a-d. of TP53 hotspot mutations are predictive of survival in primary central nervous system lymphoma patients treated with combination chemotherapy},
  url = {http://dx.doi.org/10.6084/m9.figshare.c.3595559_D1},
  year = {2016}
}

@misc{Munch-Petersen2016_2,
  abstract = {Supplemental figures 1a-c. Figure S2a-b. Supplemental figures. (PDF 474 kb)},
  author = {Munch-Petersen, Helga and Asmar, Fazila and Dimopoulos, Konstantinos and Areškevičiūtė, Aušrinė and Brown, Peter and Girkov, Mia and Pedersen, Anja and Sjö, Lene and Heegaard, Steffen and Broholm, Helle and Kristensen, Lasse and Ralfkiaer, Elisabeth and Grønbæk, Kirsten},
  doi = {10.6084/m9.figshare.c.3595559_d2},
  month = {jan},
  title = {Additional file 3: Figure S1a-c. of TP53 hotspot mutations are predictive of survival in primary central nervous system lymphoma patients treated with combination chemotherapy},
  url = {http://dx.doi.org/10.6084/m9.figshare.c.3595559_D2},
  year = {2016}
}

@article{Munch-Petersen2016_3,
  abstract = {Abstract Primary central nervous system lymphoma (PCNSL) is an aggressive variant of diffuse large B-cell lymphoma (DLBCL) confined to the CNS. TP53 mutations ( MUT-TP53 ) were investigated in the context of MIR34A/B/C - and DAPK promoter methylation status, and associated with clinical outcomes in PCNSL patients. In a total of 107 PCNSL patients clinical data were recorded, histopathology reassessed, and genetic and epigenetic aberrations of the p53-miR34-DAPK network studied. TP53 mutational status (exon 5–8), with structural classification of single nucleotide variations according to the IARC-TP53-Database, methylation status of MIR34A/B/C and DAPK, and p53-protein expression were assessed. The 57/107 (53.2 %) patients that were treated with combination chemotherapy +/− rituximab (CCT-treated) had a significantly better median overall survival (OS) (31.3 months) than patients treated with other regimens (high-dose methotrexate/whole brain radiation therapy, 6.0 months, or no therapy, 0.83 months), P },
  author = {Munch-Petersen, Helga D. and Asmar, Fazila and Dimopoulos, Konstantinos and Areškevičiūtė, Aušrinė and Brown, Peter and Girkov, Mia Seremet and Pedersen, Anja and Sjö, Lene D. and Heegaard, Steffen and Broholm, Helle and Kristensen, Lasse S. and Ralfkiaer, Elisabeth and Grønbæk, Kirsten},
  doi = {10.1186/s40478-016-0307-6},
  journal = {Acta Neuropathologica Communications},
  month = {apr},
  title = {TP53 hotspot mutations are predictive of survival in primary central nervous system lymphoma patients treated with combination chemotherapy},
  url = {https://doi.org/10.1186/s40478-016-0307-6},
  volume = {4},
  year = {2016}
}

@incollection{Treppendahl2016,
  author = {Treppendahl, Marianne B. and Kristensen, Lasse Sommer and Grønbæk, Kirsten},
  doi = {10.1016/b978-0-12-801899-6.00005-x},
  journal = {Epigenetic Biomarkers and Diagnostics},
  month = {jan},
  pages = {91-118},
  title = {Biomarkers and Methodologies for Monitoring Epigenetic Drug Effects in Cancer},
  url = {https://oadoi.org/10.1016/b978-0-12-801899-6.00005-x},
  year = {2016}
}

@article{Ørskov2017,
  author = {Ørskov, Andreas Due and Grønbæk, Kirsten},
  doi = {10.1097/ppo.0000000000000282},
  journal = {Cancer Journal},
  month = {jan},
  pages = {277-285},
  title = {DNA Methyltransferase Inhibitors in Myeloid Cancer: Clonal Eradication or Clonal Differentiation?},
  url = {https://oadoi.org/10.1097/ppo.0000000000000282},
  volume = {23},
  year = {2017}
}

Statistics

140 papers found

Refine by OA status Available from the publisher 54 Available from the author 23 Could be shared by the authors 38 Unknown/unclear sharing policy 25 Publisher forbids sharing 0

Tools

Sort by

newest first
oldest first

Export citations for current page

Refine

By title

By authors

By publication date

after

before

By document type

Journal article
Proceedings article
Book chapter
Book
Journal issue
Proceedings
Entry
Poster
Report
Thesis
Dataset
Preprint
Other document

2017

Vibe Ballegaard, Ulrik Ralfkiaer, Karin K. Pedersen, Malene Hove, Simon Koplev, Peter Brændstrup, Lars P. Ryder, Hans O. Madsen, Jan Gerstoft, Kirsten Grønbæk, Susanne D. Nielsen

MicroRNA-210, MicroRNA-331, and MicroRNA-7 Are Differentially Regulated in Treated HIV-1–Infected Individuals and Are Associated With Markers of Systemic Inflammation:

Upload
Arne Kolstad, Lone Bredo Pedersen, Christian W. Eskelund, Simon Husby, Kirsten Grønbæk, Mats Jerkeman, Anna Laurell, Riikka Räty, Erkki Elonen, Niels Smedegaard Andersen, Peter deNully Brown, Eva Kimby, Hans Bentzen, Christer Sundström, Mats Ehinger and 9 other authors

Molecular Monitoring after Autologous Stem Cell Transplantation and Preemptive Rituximab Treatment of Molecular Relapse; Results from the Nordic Mantle Cell Lymphoma Studies (MCL2 and MCL3) with Median Follow-Up of 8.5 Years

Download doi.org
Alexandra Søgaard Helbo, Fides D. Lay, Peter A. Jones, Gangning Liang, Kirsten Grønbæk

Nucleosome Positioning and NDR Structure at RNA Polymerase III Promoters

Download doi.org
Andreas Due Ørskov, Kirsten Grønbæk

DNA Methyltransferase Inhibitors in Myeloid Cancer: Clonal Eradication or Clonal Differentiation?

Upload

2016

Jakob Werner Hansen, Maj Karoline Westman, Lene Dissing Sjö, Leonie Saft, Lasse Sommer Kristensen, Andreas Due Ørskov, Marianne Treppendahl, Mette Klarskov Andersen, Kirsten Grønbaek

Mutations in idiopathic cytopenia of undetermined significance assist diagnostics and correlate to dysplastic changes: Mutations in Idiopathic Cytopenia of Undetermined Significance

Upload
Christian W. Eskelund, Arne Kolstad, Mats Jerkeman, Riikka Räty, Anna Laurell, Sandra Eloranta, Karin E. Smedby, Simon Husby, Lone B. Pedersen, Niels S. Andersen, Mikael Eriksson, Eva Kimby, Hans Bentzen, Outi Kuittinen, Grete F. Lauritzsen and 12 other authors

15-year follow-up of the Second Nordic Mantle Cell Lymphoma trial (MCL2) ; prolonged remissions without survival plateau

Download orbit.dtu.dk
Minmin Liu, Hitoshi Ohtani, Wanding Zhou, Andreas Due Ørskov, Jessica Charlet, Yang W. Zhang, Hui Shen, Stephen B. Baylin, Gangning Liang, Kirsten Grønbæk, Peter A. Jones

Vitamin C increases viral mimicry induced by 5-aza-2′-deoxycytidine

Download www.pnas.org
Andreas Glenthøj, Andreas Ørskov, Jakob Hansen, Sine Hadrup, Casey O’Connell, Kirsten Grønbæk

Immune Mechanisms in Myelodysplastic Syndrome

Download doi.org
Helga D. Munch-Petersen, Fazila Asmar, Konstantinos Dimopoulos, Aušrinė Areškevičiūtė, Peter Brown, Mia Seremet Girkov, Anja Pedersen, Lene D. Sjö, Steffen Heegaard, Helle Broholm, Lasse S. Kristensen, Elisabeth Ralfkiaer, Kirsten Grønbæk

TP53 hotspot mutations are predictive of survival in primary central nervous system lymphoma patients treated with combination chemotherapy

Download doi.org
Lasse S. Kristensen, Signe R. Michaelsen, Henrik Dyrbye, Derya Aslan, Kirsten Grunnet, Ib J. Christensen, Hans S. Poulsen, Kirsten Grønbæk, Helle Broholm

Assessment of Quantitative and Allelic MGMT Methylation Patterns as a Prognostic Marker in Glioblastoma.

Download academic.oup.com
Derya Aslan, Christian Garde, Mette Katrine Nygaard, Alexandra Søgaard Helbo, Konstantinos Dimopoulos, Jakob Werner Hansen, Marianne Tang Severinsen, Marianne Bach Treppendahl, Lene Dissing Sjø, Kirsten Grønbæk, Lasse Sommer Kristensen

Tumor suppressor microRNAs are downregulated in myelodysplastic syndrome with spliceosome mutations

Download www.impactjournals.com
Lasse Kristensen, Jakob Hansen, Søren Kristensen, Dorte Tholstrup, Laurine Harsløf, Ole Pedersen, Peter De Nully Brown, Kirsten Grønbæk

Additional file 1: Table S1. of Aberrant methylation of cell-free circulating DNA in plasma predicts poor outcome in diffuse large B cell lymphoma

Download dx.doi.org
Lasse Kristensen, Jakob Hansen, Søren Kristensen, Dorte Tholstrup, Laurine Harsløf, Ole Pedersen, Peter De Nully Brown, Kirsten Grønbæk

Additional file 2: Figure S1. of Aberrant methylation of cell-free circulating DNA in plasma predicts poor outcome in diffuse large B cell lymphoma

Download dx.doi.org
Helga Munch-Petersen, Fazila Asmar, Konstantinos Dimopoulos, Aušrinė Areškevičiūtė, Peter Brown, Mia Girkov, Anja Pedersen, Lene Sjö, Steffen Heegaard, Helle Broholm, Lasse Kristensen, Elisabeth Ralfkiaer, Kirsten Grønbæk

Additional file 2: Tables S1a-d. of TP53 hotspot mutations are predictive of survival in primary central nervous system lymphoma patients treated with combination chemotherapy

Download dx.doi.org
Caspar da Cunha-Bang, Klaus Rostgaard, Jacob Simonsen, Christian H. Geisler, Henrik Frederiksen, Henrik Hjalgrim, Kirsten Grønbæk, Carsten Utoft Niemann

Increased Risk of Second Hematological and Non-Hematological Malignancies in CLL Patients Treated with Chemotherapy As Compared to Untreated Patients and Matched Controls

Upload
Marianne B. Treppendahl, Lasse Sommer Kristensen, Kirsten Grønbæk

Biomarkers and Methodologies for Monitoring Epigenetic Drug Effects in Cancer

Upload
Lasse Sommer Kristensen, Jakob Werner Hansen, Søren Sommer Kristensen, Dorte Tholstrup, Laurine Bente Schram Harsløf, Ole Birger Pedersen, Peter De Nully Brown, Kirsten Grønbæk

Aberrant methylation of cell-free circulating DNA in plasma predicts poor outcome in diffuse large B cell lymphoma

Download doi.org
Lasse Kristensen, Jakob Hansen, Søren Kristensen, Dorte Tholstrup, Laurine Harsløf, Ole Pedersen, Peter De Nully Brown, Kirsten Grønbæk

Additional file 3: Figure S2. of Aberrant methylation of cell-free circulating DNA in plasma predicts poor outcome in diffuse large B cell lymphoma

Download dx.doi.org
Lasse Kristensen, Jakob Hansen, Søren Kristensen, Dorte Tholstrup, Laurine Harsløf, Ole Pedersen, Peter De Nully Brown, Kirsten Grønbæk

Additional file 4: Figure S3. of Aberrant methylation of cell-free circulating DNA in plasma predicts poor outcome in diffuse large B cell lymphoma

Download dx.doi.org
Helga Munch-Petersen, Fazila Asmar, Konstantinos Dimopoulos, Aušrinė Areškevičiūtė, Peter Brown, Mia Girkov, Anja Pedersen, Lene Sjö, Steffen Heegaard, Helle Broholm, Lasse Kristensen, Elisabeth Ralfkiaer, Kirsten Grønbæk

Additional file 3: Figure S1a-c. of TP53 hotspot mutations are predictive of survival in primary central nervous system lymphoma patients treated with combination chemotherapy

Download dx.doi.org

Missing publications? Read more about our data sources.